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1. Introduction
Parkinson’s disease (PD) is a prevalent neurodegenerative movement disorder whose
occurrence crosses geographic, racial and social boundaries affecting 1-2% of the population
above the age of 65 (Dorsey et al., 2007). Clinically, the disease is attended by a constellation
of motoric deficits that progressively worsen with age, which ultimately leads to near total
immobility. Although pathological changes are distributed in the PD brain (Braak et al.,
2003), the principal lesion that underlies the characteristic motor phenotype of PD patients is
unequivocally the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of
the midbrain. This neuronal loss results in a severe depletion of striatal dopamine (DA) and
thereby an impaired nigrostriatal system that otherwise allows an individual to execute
proper, coordinated movements. Accordingly, pharmacological replacement of brain DA via
L-DOPA administration represents an effective symptomatic recourse for the patient (espe‐
cially during the initial stages of the disease) and remains a clinical gold standard treatment
for PD. However, neither L-DOPA nor any currently available therapies could slow or stop
the insidious degenerative process in the PD brain. Thus, PD remains an incurable disease.
Invariably, the debilitating nature and morbidity of the disease present significant healthcare,
social, emotional and economic problems. As the world population rapidly ages, these
problems undoubtedly would also increase. According to a recent report, more than 4 million
individuals in Europe’s five most and the world’s ten most populous countries are currently
afflicted with PD (Dorsey et al., 2007). In less than 20 years’ time, the number of PD sufferers
is projected to increase to close to 10 million (i.e. in 2030). This is definitely a worrying trend,
and one that aptly emphasizes the urgency to develop more effective treatment modalities for
the PD patient. Towards this endeavour, a better understanding of the molecular mechanism(s)
that underlies the pathogenesis of PD would definitely be helpful, as the illumination of which
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would allow the identification and therapeutic exploitation of key molecules/events involved
in the pathogenic process.
Although a subject of intense research, the etiology of PD unfortunately remains incompletely
understood. However, a broad range of studies conducted over the past few decades, including
epidemiological, genetic and post-mortem analysis, as well as in vitro and in vivo modelling,
have contributed significantly to our understanding of the pathogenesis of the disease. In
particular, the recent identification and functional characterization of several genes, including
α-synuclein, parkin, DJ-1, PINK1 and LRRK2, whose mutations are causative of rare familial
forms of PD have provided tremendous insights into the molecular pathways underlying
dopaminergic neurodegeneration (Lim and Ng, 2009; Martin et al., 2011). Collectively, these
studies implicate aberrant protein and mitochondrial homeostasis as key contributors to the
development of PD, with oxidative stress likely acting an important nexus between the two
pathogenic events.
2. Aberrant protein homeostasis & PD
Perhaps the most glaring evidence suggesting that protein homeostasis has gone awry in the
PD brain is the presence of intra-neuronal inclusions, known as Lewy Bodies (LBs), in affected
regions of the diseased brain in numbers that far exceed their occasional presence in the normal
brain (Lewy, 1912). These signature inclusions of PD comprise of a plethora of protein
constituents that include several PD-linked gene products such as α-synuclein, parkin, DJ-1,
PINK1 and LRRK2. In a recent report, Wakabayashi and colleagues have documented more
than 90 components of the LB and have grouped them into 13 functional groups (Table 1)
(Wakabayashi et al., 2012). Among these, α-synuclein is recognized as the major component
of LB and thought to be the key initiator of LB biogenesis.
However, whether LB biogenesis represents a cytoprotective or pathogenic mechanism in PD
remains debatable. Notwithstanding this, how proteins aggregate to form LB is intriguing in
the first place, as the cell is endowed with several complex surveillance machineries to detect
and repair faulty proteins, and also destroy those are beyond repair rapidly (Fig. 1). In this
surveillance system, the chaperones (comprising of members of the heat-shock proteins)
represent the first line of defense in ensuring the correct folding and refolding of proteins
(Liberek et al., 2008). When a native folding state could not be attained, the chaperones will
direct the misfolded protein for proteolyic removal typically by the proteasome. Proteins that
are destined for proteasome-mediated degradation are usually added a chain of ubiquitin via
a reaction cascade that involves the ubiquitin-activating (E1), -conjugating (E2) and -ligating
(E3) enzymes, whereby successive iso-peptide linkages are formed between the terminal
residue (G76) of one ubiquitin molecule and a lysine (K) residue (most commonly K48) within
another. The (G76-K48) polyubiquitinated substrate is then recognized by the 26S proteasome
as a target for degradation (Pickart and Cohen, 2004). It is noteworthy to mention that although
the G76-K48 chain linkage is the most common form of polyubiquitin, ubiquitin self-assembly
can occur at any lysine residues within the molecule (at positions 6, 11, 27, 29, 33, 48 and 63)
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(Pickart, 2000; Peng et al., 2003). In addition, proteins can also be monoubiquitinated. Notably,
both K63-linked polyubiquitination and monoubiquitination of proteins are not typically
associated with proteasome-mediated degradation (Pickart, 2000; Peng et al., 2003).
Group Components Remarks
1 α-synuclein; Neurofilaments Structural Elements
2 Agrin; 14-3-3; Synphilin-1; Tau α-synuclein-binding proteins
3 Dorfin; GSK-3β; NUB1; Parkin; Pin1; SIAH-1 Synphilin-1-binding proteins
4
Ubiquitin; E1; UbcH7; TRAF6; TRIM9; Proteasome subunits;
PA700; PA28; β-TrCP; Cullin-1; HDAC4; NEDD8; p38; p62
(Sequestosome 1); ROC1; UCHL1
UPS-related proteins
5 LC3; GABARAP; GATE-16; Glucocerebrosidase; NBR-1 Autophagosome-lysosome system
6 γ-tubulin; HDAC6; Peri-centrin Aggresome-related proteins
7 DJ-1; CHIP; Clusterin/apolipoprotein J; DnaJB6; Heat ShockProteins; Torsin A, SOD1 & 2; FOXO3a Stress response-related proteins
8
CaMKII; Casein Kinase II; CDK5, G-Protein Coupled Receptor
Kinase 5; LRRK2; PINK1; IκBα; NFκB; p35; phospho-lipase C-δ;
Tissue Transglutaminase
Signal transduction-related proteins
9 MAP1B; MAP2; Sept4/H5 Cytoskeletal proteins
10 Cox IV; Cytochrome C; Omi/HtrA2 Mitochondria-related proteins
11 Cyclin B; Retinoblastoma Protein Cell cycle proteins
12
Amyloid Precursor Protein; Calbindin; Choline Acetyltransferase;
Chromogranin A; Synaptophysin; Synaptotagmin; Tyrosine
Hydroxylase; VMAT2
Cytosolic Proteins
13 Complement Proteins; Immunoglobulin Immune-related proteins
Table 1. Components of Lewy Body (Wakabayashi et al., 2012)
Whilst the coupling of chaperone and ubiquitin protein system (UPS) provides an efficient
way for the cell to deal with protein misfolding, there are times when the capacity of these
systems may be exceeded by the production of misfolded proteins (e.g. under conditions of
cellular stress). In such cases, aggregation-prone proteins that failed to be degraded may be
transported along microtubules in a retrograde fashion to the microtubule organizing center
to form an “aggresome”, a term originally coined by Johnston and Kopito more than a decade
ago (Johnston et al., 1998). According to the model, aggresome formation represents a cellular
response towards proteasome impairments and their localization to the juxta-nuclear region
is to facilitate their capture by lysosomes and thereby their clearance by macroautophagy
(hereafter referred to as autophagy). Consistent with this, aggregation-prone proteins often
generate aggresome-like structures when ectopically expressed in cultured cells in the
presence of proteasome inhibition (Wong et al., 2008). Moreover, several groups including ours
have demonstrated that autophagy induction promotes the clearance of aggresomes whereas
the reverse is true when the bulk degradation system is inhibited (Fortun et al., 2003; Iwata et
al., 2005b; Opazo et al., 2008; Wong et al., 2008).
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Together, the chaperone, ubiquitin-proteasome and autophagy systems thus function in
synergism to effectively counterbalance the threat of protein misfolding and aggregation.
Accordingly, aberrations in one or more of these systems would be expected to promote
protein aggregation and inclusion body formation, as in the case of affected neurons in the PD
brain where LBs occur.
Figure 1. Schematic depiction of the collaboration among the chaperone, ubiquitin-proteasome and autophagy sys‐
tems in the maintenance of intracellular protein homeostasis.
3. Biogenesis of Lewy bodies – An aggresome-related process reflecting
failed autophagy?
As mentioned earlier, α-synuclein is a major component of LBs, suggesting that aberrant
α-synuclein homeostasis contributes to the biogenesis of these inclusion bodies in the PD
brain. The presynaptic terminal-enriched α-synuclein protein is an interesting molecule in
that  it  is  typically unfolded (or  intrinsically disordered) in its  native state,  although the
protein is extremely sensitive to its environment and can be moulded into an assortment
of  structurally  unrelated  conformations  including  a  fibrillization-prone  partially  folded
structure as well as various α-helical and β-sheet species occurring in both monomeric and
oligomeric states (Uversky, 2007). Along with this conformation flexibility, α-synuclein also
tends  to  misfold  and  becomes  aggregated  in  the  process.  PD-associated  mutations,
including missense  substitutions  (A53T,  A30P and E46K),  duplication or  triplication are
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known to enhance α-synuclein accumulation and aggregation (Giasson et al., 1999; Narhi
et al., 1999; Conway et al., 2000; Uversky, 2007). Further, several groups have demonstrat‐
ed in different experimental models that various exogenous neurotoxicants linked to PD,
including pesticides, herbicides and metal ions, significantly accelerate the aggregation of
α-synuclein  (Manning-Bog  et  al.,  2002;  Uversky  et  al.,  2002;  Sherer  et  al.,  2003).  Not
surprisingly,  α-synuclein  accumulation  and aggregation  can  lead  to  impairments  of  the
chaperone  and  UPS  systems  [For  a  recent  review,  see  (Tan  et  al.,  2009)].  Under  such
conditions, the isolation of α-synuclein aggregates into an aggresome would represent an
alternative way by which the protein could be cleared, i.e. via autophagy. Indeed, emerging
evidence suggest that LB biogenesis may be an aggresome-related process (Olanow et al.,
2004). Because the protofibrillar, oligomeric forms of α-synuclein are thought to be more
toxic  than  fibrillar,  aggregated  α-synuclein  species,  aggresome  formation  may  also  be
regarded as a “protective” response that serves as a trap to immobilize soluble toxic forms
of  α-synuclein.  However,  this  process  has  to  be  coupled  to  the  active  removal  of  the
aggresomes by autophagy, as the unregulated growth of an inclusion body could conceiv‐
ably affect cellular functions, physically or otherwise.
The  relevance  of  aggresome  formation  to  LB  biogenesis  in  PD  is  exemplified  by  their
striking similarities to each other in terms of structural organization, protein composition
and intracellular localization (Olanow et al., 2004). For example, aggresome-related proteins
such as γ-tubulin and HDAC6 can be found in LB (Table 1). HDAC6 plays an important
role during aggresome formation by facilitating the retrograde transport of ubiquitinated
misfolded proteins along the microtubule network to the γ-tubulin-positive MTOC by the
dynein motor complex (Kawaguchi et al.,  2003). Moreover, LBs are also immunopositive
for p62 and NBR1, which are autophagy adapter proteins capable of binding to ubiquitinat‐
ed substrates and the autophagosome protein LC3 (Bjorkoy et al., 2005; Pankiv et al., 2007;
Kirkin et al., 2009). By virtue of this binding property, p62 and NBR1 may provide a link
between  aggresome-related  proteins  and  their  clearance  by  the  autophagy  machinery.
Interestingly,  all  the  three  ubiquitin-binding  autophagy  receptors,  i.e.  p62,  HDAC6 and
NBR1, show preference for K63-linked polyubiquitin chains (Olzmann et al., 2007; Tan et
al.,  2008a;  Kirkin  et  al.,  2009),  suggesting  that  this  form  of  ubiquitin  modification  may
underlie the formation as well  as autophagic degradation of  protein aggregates.  Consis‐
tent with this, we found that K63-linked ubiquitination promotes the formation of inclusion
bodies associated with PD and other neurodegenerative diseases and importantly, acts as
a cargo selection signal for their subsequent removal by autophagy (Tan et al., 2008a; Tan
et al.,  2008b). As per our original proposal (Lim et al.,  2006), it is tempting to think that
the cell may switch to an alternative, proteasome-independent form of ubiquitination under
conditions of proteasome-related stress that could help divert  cargo proteins away from
an  otherwise  overloaded  proteasome.  All  these  would  culminate  to  the  ultimate  clear‐
ance of these proteins by autophagy (Fig. 1).
What remains curious about LB biogenesis  is  that  it  apparently takes place in the pres‐
ence of constitutive autophagy, which is a characteristic of post-mitotic neurons (Wong and
Cuervo, 2010). Moreover, α-synuclein is itself a substrate for autophagy (Webb et al., 2003).
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Although α-synuclein can also be degraded by the proteasome, the aggregates of which
appear to be preferentially cleared by the autophagy system (Petroi et al.,  2012). Consis‐
tent with this,  autophagy is recruited as the primary removal system in transgenic mice
over-expressing oligomeric species of α-synuclein (Ebrahimi-Fakhari et al., 2011). Further,
the  protein  can  also  be  removed  via  chaperone-mediated  autophagy  (CMA),  a  special‐
ized form of lysosomal degradation by which proteins containing a particular pentapep‐
tide motif related to KFERQ are transported across the lysosomal membrane via the action
of  the  integral  membrane  protein  LAMP-2A  and  both  cytosolic  and  lumenal  hsc70
(Klionsky  et  al.,  2011).  Notably,  the  intralysosomal  level  of  α-synuclein  is  significantly
increased  along  with  LAMP-2A and hsc70  in  mice  treated  with  the  herbicide  paraquat
(which induces parkinsonism) or expressing α-synuclein as a transgene (Mak et al., 2010).
Thus in theory, the level of α-synuclein, whether present as soluble or aggregated species,
should be effectively managed in neurons under normal conditions or even when they are
undergoing stress. Indeed, even in the PD brain, LB takes a significant length of time to
develop. Given this, and that the autophagy system arguably represents the final line of
cellular  defense against  the buildup of  protein aggregates,  the simplest  explanation that
could account for the presence of LB in PD is that the autophagy system has either become
suboptimal in its function or is otherwise impaired altogether during the disease pathogen‐
esis process.
4. Autophagy and PD
Morphological evidence of autophagic vacuole (AV) accumulation is certainly evident in PD
as well as in several other neurodegenerative disorders (Anglade et al., 1997). However,
whether the phenomenon represents attempts by the neuron to clean up its cobwebs of
aggregated proteins, or a prelude to cell death, or simply a failure in AV consumption remains
poorly understood. Notwithstanding this, two elegant studies conducted in 2006 aptly
illustrated the importance of competent autophagy function to neuronal homeostasis (Hara et
al., 2006; Komatsu et al., 2006). By means of targeted genetic disruption of essential components
of the autophagy process (Atg5 or Atg7), these studies demonstrated that ablation of autoph‐
agy function in neural cells of mice results in extensive neurodegeneraion that is accompanied
by widespread inclusion pathology, suggesting that autophagy failure can precipitate protein
aggregation and subsequent cell death in affected neurons.
Supporting a role for failed autophagy in PD in the face of α-synuclein accumulation, α-
synuclein was recently demonstrated to inhibit  autophagy when over-expressed, both in
vitro  and in vivo  (Winslow et al.,  2010).  The inhibition apparently occurs at a very early
stage of autophagosome formation, which is likely a result of disrupted localization and
mobilization of  Atg9,  a  multi-spanning membrane protein whose associated vesicles  are
important sources of membranes for the synthesis of early autophagosomes (Yamamoto et
al.,  2012).  Interesting,  the  reverse,  i.e.  autophagy  enhancement,  was  observed  when  α-
synuclein is  depleted via  RNAi-mediated knockdown (Winslow et  al.,  2010),  suggesting
that  the protein might play a regulatory role  in the synthesis  of  autophagosome.  More‐
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over,  targeted  disruption  of  autophagy  (via  Atg7  deletion)  in  midbrain  dopaminergic
neurons  results  in  abnormal  presynaptic  accumulation  of  α-synuclein  that  is  accompa‐
nied by dendritic and axonal dystrophy, reduced striatal DA content,  and the formation
of somatic and dendritic ubiquitinated inclusions (Friedman et al.,  2012). Significant age-
dependent loss of nigral dopaminergic neurons were also recorded in these Atg7 condition‐
ally knockout mice (Atg7-cKOTH), with 9 month old Atg7-cKOTH mice exhibiting about 40%
reduction  in  the  number  of  SN  neurons  that  is  accompanied  by  markedly  decreased
spontaneous motor activity and coordination relative to controls  (Friedman et  al.,  2012).
Together,  these results  suggest  that  failure in autophagy function precipitates inclusions
formation in dopaminergic neurons that leads to their demise.
Besides macroautophagy, α-synuclein can also affect the function of CMA. For example,
disease-associated  α-synuclein  mutants  bind  to  the  CMA  lysosomal  receptor  with  high
affinity but are poorly translocated, resulting in the blockage of uptake and degradation
of CMA substrates (Cuervo et al.,  2004). The increase in cytosolic α-synuclein levels that
ensued could favour its aggregation and concomitantly, amplify the burden of misfolded
protein load for the cell. Interestingly, DA modification of α-synuclein also impairs CMA-
mediated degradation by a similar mechanism (Martinez-Vicente et al., 2008). In this case,
membrane-bound DA-α-synuclein monomers appear to seed the formation of oligomeric
complexes, which consequently placed the translocation complex under siege. Consistent
with  this,  CMA inhibition  following  L-DOPA treatment  is  more  pronounced  in  ventral
midbrain  cultures  containing  dopaminergic  neurons  than  in  non-DA producing  cortical
neurons.  Importantly,  α-synuclein  appears  to  be  the  principal  mediator  of  DA-induced
blockage of  CMA, as  ventral  midbrain  cultures  derived from α-synuclein  null  mice  are
relatively spared from the inhibitory effects of DA on CMA (Martinez-Vicente et al., 2008).
More  recently,  Malkus  and  Ischiropoulos  demonstrated  that  CMA  activity  in  the  adult
brain of A53T α-synuclein-expressing transgenic mice varies across different regions, with
brain  regions  vulnerable  to  α-synuclein  aggregation  displaying  marked  deficiencies  in
CMA  (Malkus  and  Ischiropoulos,  2012).  Their  results  support  an  integral  role  for  the
lysosome  in  maintaining  α-synuclein  homeostasis  and  at  the  same  time,  provides  an
explanation to why certain brain regions are vulnerable to inclusion formation and cellular
dysfunction while others are spared.
Perhaps the most direct evidence linking lysosomal dysfunction to PD is the demonstration
that loss-of-function mutations in a gene encoding for the lysosomal P-type ATPase named
ATP13A2 cause a juvenile and early-onset form of parkinsonism that is also characterized by
pyramidal degeneration and dementia (Ramirez et al., 2006). In patient-derived fibroblasts as
well as in ATP13A2-silenced primary mouse neurons, deficient ATPase function results in
impaired lysosomal degradation capacity that concomitantly enhanced the accumulation and
toxicity of α-synuclein (Usenovic et al., 2012). Importantly, silencing of endogenous α-
synuclein ameliorated the toxicity in neurons depleted of ATP13A2, suggesting that ATP13A2-
induced parkinsonism may be contributed by α-synuclein accumulation amid functional
impairments of the lysosome. Supporting this, overexpression of wild type ATP13A2 sup‐
presses α-synuclein-mediated toxicity in C. elegans while knockdown of ATP13A2 expression
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promotes the accumulation of misfolded α-synuclein in the animal (Rappley et al., 2009).
Together, these studies demonstrate a functional link between ATP13A2-related lysosomal
dysfunction and α-synuclein in promoting neurodegeneration.
Besides α-synuclein and ATP13A2, several other PD-linked genes have also been associated
directly or indirectly with the autophagic process. For example, emerging evidence suggest
that mutations in LRRK2 promote dysregulation in autophagy, although the role of LRRK2 in
controlling autophagy-lysosome pathway is likely to be complex (discussed further in section
6). In the case of parkin, which has the ability to promote K63-linked ubiquitination, we and
others have shown that the ubiquitin ligase is involved in aggresome formation and thereby
their removal via autophagy (at least indirectly) (Lim et al., 2005; Olzmann et al., 2007).
Consistent with its role as an “aggresome-promoter”, parkin-related cases are frequently
(although not exclusively) devoid of classic LBs, as revealed by a number of autopsy studies
(Takahashi et al., 1994; Mori et al., 1998; Hayashi et al., 2000). In recent years, the attention to
parkin-autophagy axis has however shifted towards its ability to remove damaged mitochon‐
dria via a specialized form of autophagy known as “mitophagy”, a term originally coined by
Lemasters (Lemasters, 2005). Accordingly, impairment in mitochondrial quality control due
to failed mitophagy in parkin-deficient neurons is now thought to be a key mechanism that
predisposes them to degeneration.
5. Mitophagy and PD
A role for mitochondria dysfunction in the pathogenesis of PD has long been appreciated.
Through post-mortem analysis performed as early as 1989, several groups have recorded a
significant reduction in the activity of mitochondrial complex I as well as ubiquinone (co-
enzyme Q10) in the SN of PD brains (Schapira et al., 1989; Shults et al., 1997; Keeney et al.,
2006). Moreover, mitochondrial poisoning recapitulates PD features in humans and represents
a popular strategy to model the disease in animals (Dauer and Przedborski, 2003). Similarly,
impairment of mitochondrial homeostasis via genetic ablation of TFAM, a mitochondrial
transcription factor, in dopaminergic neurons of mice (named MitoPark mouse) results in
energy crisis and neurodegeneration (Sterky et al., 2011).
Rather than being solitary and static structures as depicted in many textbooks, mitochondria
are now recognized to be dynamic and mobile organelles that constantly undergo membrane
remodeling through repeated cycles of fusion and fission as well as regulated turnover via
mitophagy. These processes help to maintain a steady pool of healthy mitochondrial essential
for energy production and beyond (e.g. calcium homeostasis). Following the seminal discovery
by Youle group that identified parkin as a key mammalian regulator of mitophagy (Narendra
et al., 2008), intensive research is now focused on elucidating the precise mechanism under‐
lying parkin-mediated mitophagy and whether impaired clearance of damaged mitochondria
may trigger the demise of dopaminergic neurons in the PD brain.
Mechanistically, the picture regarding parkin-mediated mitophagy that has emerged thus far
is depicted in Figure 2.
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Figure 2. Model of Parkin/PINK1-mediated mitophagy
In this model, another PD-linked gene known as PINK1, which is a mitochondrial serine/
threonine kinase, collaborate closely with parkin to bring about the mitophagy process. Briefly,
a key initial event that occurs upon mitochondrial depolarization is the selective accumulation
of PINK1 in the outer membrane of the damaged organelle. Normally, PINK1 accumulation
in healthy mitochondria is prevented by the sequential proteolytic actions of mitochondrial
processing peptidase (MPP) and presenilin-associated rhomboid-like protease (PARL) that
rapidly cleaves the protein to generate an unstable 53 kDa PINK1 species that is usually
degraded by the proteasome or by an unknown “proteasome-like” protease (Becker et al.,
2012; Greene et al., 2012). In depolarized mitochondria, PINK1 stabilization on the outer
membrane enables the protein to recruit parkin to the organelle, a process that is apparently
dependent on PINK1 autophosphorylation at Ser228 and Ser402 (Okatsu et al., 2012). Once
recruited onto the mitochondria, parkin becomes activated and promotes the ubiquitination
and subsequent degradation of many outer membrane proteins (Chan et al., 2011; Yoshii et
al., 2011) including the pro-fusion mitofusin proteins (Poole et al., 2010; Ziviani et al., 2010),
the elimination of which is thought to prevent unintended fusion events involving damaged
mitochondria and thereby their re-entry into undamaged mitochondrial network from
occurring. Mitophagy induction then occurs, which likely involves parkin-mediated K63
ubiquitination that will help recruit the autophagy adaptors HDAC6 and p62 that subse‐
quently lead to mitochondrial clustering around the peri-nucleus region. By virtue of their
association with the autophagy process, the concerted actions of p62 and HDAC6 will
presumably facilitate the final removal of damaged mitochondria by the lysosome (Ding et al.,
2010; Geisler et al., 2010; Lee et al., 2010). However, a recent study from Mizushima’s lab
revealed that the initial cargo recognition step of mitophagy does not involves the interaction
between LC3 and the adaptor molecules. Rather, parkin recruitment on the mitochondria
induces the formation of ULK1 (Atg1) puncta and Atg9 structures (Itakura et al., 2012). Because
ULK1 complex functions as an essential upstream nucleation step of the hierachical autophagy
cascade, their results suggest that mitophagosome is generated in a de novo fashion on
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damaged mitochondria. Autophagosomal LC3 is however important for the efficient incor‐
poration of damaged mitochondria into the autophagosome at a later stage. Notwithstanding
this, how parkin participates in the de novo synthesis of isolation membrane awaits further
clarifications. Interestingly, the whole mitophagy process bears striking resemblance to the
formation and autophagic clearance of aggresomes. Indeed, we have termed the mitochondrial
clustering phenomenon as (formation of) “mito-aggresomes” (Lee et al., 2010). Importantly,
several groups, including ours, have demonstrated that PD-associated parkin mutants are
defective in supporting mitophagy due to distinct problem at recognition, transportation or
ubiquitination of impaired mitochondria (Lee et al., 2010; Matsuda et al., 2010), thereby
implicating dysfunctional mitophagy in the development of parkin-related parkinsonism.
Given the pivotal role of parkin/PINK1 pathway in mitochondrial quality control, it is perhaps
not surprising to note that deficiency in parkin or PINK1 function results in the accumulation
of abnormal mitochondria in several parkin/PINK1-related PD models. This defect is perhaps
most prominently observed in Drosophila parkin or PINK1 mutants, especially in their flight
musculature, which is plagued by pronounced mitochondrial lesions and muscle degeneration
(Greene et al., 2003; Clark et al., 2006; Park et al., 2006; Wang et al., 2007). Importantly, parkin
over expression in pink1-/- flies significantly ameliorates all the mutant phenotypes, although
the reverse, does not happen, i.e. pink1 over expression in parkin null flies does not compensate
for the loss of parkin function. These results suggest that parkin acts in the same pathway but
downstream of pink1 (Clark et al., 2006; Park et al., 2006). The hierachy is consistent with the
proposed model of parkin/PINK1 pathway in the regulation of mitochondrial quality control,
although parkin in this case can apparently do the job in the complete absence of pink1.
Notably, several other studies also suggested that mitophagy can take place in a PINK1-
deficient background (Dagda et al., 2009; Cui et al., 2010; Dagda et al., 2011). Conversely, Seibler
and colleagues found PINK1 to be essential for parkin-mediated mitophagy. They demon‐
strated that parkin recruitment to depolarized mitochondria is impaired in human dopami‐
nergic neurons derived via the induced pluripotent stem cells route from PINK1-related PD
patients, a defect that can be rescued by the re-introduction of wild-type PINK1 into PINK1-
deficient neurons (Seibler et al., 2011).
As with the case with virtually all the biological models initially proposed, the parkin/PINK1
mitophagy model is currently less than perfect and clearly needs be continually updated with
each new piece of significant data. The relevance of mitophagy to sporadic PD is also debatable,
although we and others have previously shown that parkin dysfunction (presumably trigger‐
ing mitophagy deficiency) may also underlie the pathogenesis of sporadic PD (Pawlyk et al.,
2003; LaVoie et al., 2005; Wang et al., 2005a). Perhaps one of most challenging tasks at hand is
to demonstrate unequivocally that mitophagy impairment, instead of a generalized impair‐
ment in the autophagy process, contributes directly to neurodegeneration in vivo. This would
require the genetic differentiation of targeted components that are exclusively involved in
mitophagy. Currently, key components of mitophagy and autophagy tend to overlap. Even
parkin appear to subserve both types of autophagy processes (and more). Thus, although
mitochondrial quality control is invariably important for neuronal survival, whether failure
in the removal of damaged mitochondria is in itself a driver of disease pathogenesis or is a
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consequence of a progressive and general decline in autophagy function in the PD brain
remains to be clarified.
6. Autophagy induction as therapeutic strategy for PD?
If failure in autophagy function were to underlie PD pathogenesis, it follows intuitively that
stimulation of autophagy in the PD brain might be beneficial for the patient. Indeed, work
from Rubinsztein lab and others have demonstrated that autophagy enhancement promotes
beneficial outcomes in several experimental models of PD, supporting that such an approach
could represent a viable therapeutic strategy (Rubinsztein et al., 2012).
Notably, most neurodegenerative disease-associated proteins, including α-synuclein, that are
prone to aggregation are substrates of autophagy. Accordingly, pharmacological or genetic
enhancement of autophagy can in theory help remove these aggregation-prone proteins and
concomitantly reduce their associated toxicity. Rapamycin, an inducer of mTOR (mammalian
Target of Rapamycin), is widely established to be a potent autophagy inducer. Expectedly,
rapamycin treatment of cellular or animal models of α-synucleinopathies reduces the levels
of both soluble and aggregated species of α-synuclein in an autophagy-dependent manner
(Crews et al., 2010). Similarly, trehalose also accelerates the clearance of α-synuclein by means
of its ability to induce autophagy, albeit in an mTOR-independent manner (Sarkar et al.,
2007). Further, trehalose-treated cells are protected against subsequent pro-apoptotic insults.
Together, trehalose and rapamycin exert an additive effect in the clearance of aggregate-prone
proteins (Sarkar et al., 2007). Perhaps unsurprisingly, rapamycin can also rescue failed
mitophagy in parkin deficient cells and result in improved mitochondrial function (Siddiqui
et al., 2012), suggesting that generalized autophagy activation can help clean up all the cellular
“cobwebs” be it protein aggregates or damaged organelles. More recently, Steele and collea‐
gues showed that latrepirdine, a neuroactive compound associated with enhanced cognition
and neuroprotection, also stimulates the degradation of α-synuclein and concomitantly
protects against α-synuclein-induced toxicity in 3 model systems: yeast, differentiated SH-
SY5Y cells and wild type mouse (Steele et al., 2012). The beneficial effects of latrepirdine again
appear to be related to autophagy induction, as evident by the elevation of several autophagy
markers in mouse brain following chronic administration of the compound. Using a genetic
approach, Spencer and colleagues demonstrated via lentivirus-mediated gene transfer of
beclin 1, a key promoter of autophagy, that genetic enhancement of autophagy in α-synuclein
overexpressing mice ameliorates the synaptic and dendritic pathology in these transgenic
animals and reduces the accumulation of the protein in vivo (Spencer et al., 2009). Taken
together, these studies support the therapeutic applications of autophagy induction in PD,
particularly in preventing the accumulation of α-synuclein.
Notwithstanding the above promising findings regarding the protective effects of autoph‐
agy  induction,  it  is  important  to  recognize  that  autophagy induction  is  a  “double-edge
sword” that can cut both ways, i.e.  being protective or pro-death under different condi‐
tions. One therefore have to consider this caveat in considering autophagy induction as a
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therapeutic  strategy  for  PD.  Notably,  the  parkinsonian  neurotoxin  MPP+  that  induces
selective loss of dopaminergic neurons has been demonstrated by several groups to activate
autophagy  (Zhu et  al.,  2007;  Xilouri  et  al.,  2009;  Wong et  al.,  2011),  a  process  that  ap‐
pears to act through the dephosphorylation of LC3 (which enhances its recruitment into
autophagosomes) (Cherra et al., 2010) and/or CDK5-mediated phosphorylation of endophi‐
lin B1 (which promotes its dimerization and recruitment of the UVRAG/Beclin 1 complex
to induce autophagy) (Wong et al., 2011). In this case, autophagy induction is apparently
harmful to dopaminergic neurons. Moreover, stimulation of autophagy also contributes to
neuronal death induced by overexpression of α-synuclein (Xilouri et al., 2009). Converse‐
ly, inhibition of autophagy pharmacologically with 3-methylalanine (3-MA) or genetically
via Atg5 or Atg12 gene silencing significantly attenuates neuronal loss associated with MPP
+ treatment or mutant α-synuclein expression, as is the case with knockdown of CDK5 or
endophilin B1 (Wong et al.,  2011). Along these lines, we found that mutant α-synuclein-
associated toxicity is aggravated by the accumulation of iron, which act together to trigger
autophagic  cell  death.  The  toxicity  that  α-synuclein-iron  elicits  can  be  ameliorated  by
pharmacological  inhibition  of  autophagy  (Chew  et  al.,  2011).  Interestingly,  autophagy
activation  elicited  by  mutant  α-synuclein  overexpression  can  also  result  in  excessive
mitophagy and thereby unintended loss of mitochondria, which in turn promotes bioener‐
getics  deficit  and  neuronal  degeneration  (Choubey  et  al.,  2011).  Further  supporting  a
“pathological” role for autophagy, loss of DJ-1 function associated with recessive parkin‐
sonism has  been found to  increase  (instead of  decrease)  autophagic  flux,  although it  is
currently  unclear  how  this  relates  to  neuronal  death  in  the  context  of  DJ-1  deficiency
(Irrcher et al., 2010).
Finally, mutations in LRRK2, which currently represent the most prevalent genetic contributor
to PD, are also implicated in aberrant autophagy induction. For example, transgenic mice
expressing disease-associated LRRK2 mutants (R1441C and G2019S) frequently exhibit
increased incidence of autophagic vacuoles in their brain (Ramonet et al., 2011). Similarly, cells
expressing G2019S LRRK2 mutant show increase autophagosome content and autophagy-
dependent shortening of neurites (Plowey et al., 2008). Conversely, ablation of LRRK2 in mice
promotes impairment of the autophagy pathway as evident by the accumulation of p62,
lipofuscin granules, ubiquitinated proteins and α-synuclein-positive inclusions in their
kidneys (Tong et al., 2010). The relationship between LRRK2 and autophagy is however
complicated. For example, Gomez-Suaga and colleagues have recently demonstrated that
LRRK2-induced accumulation of autophagosome is related to the ability of the kinase to
activate a calcium-dependent protein kinase kinase-beta (CaMKK-beta)/adenosine mono‐
phosphate (AMP)-activated protein kinase (AMPK) pathway via modulation of NAADP-
dependent Ca2+ channel on lysosomal membrane (Gomez-Suaga et al., 2012). However, they
also detected at the same time a reduction in the acidification of lysosomes that can compromise
autophagosome turnover and thereby autophagy (Gomez-Suaga et al., 2012), suggesting that
autophagy is actually impaired rather than activated in LRRK2-expressing cells. Consistent
with this, another study revealed that the expression of LRRK2 R1441C mutant leads to
impaired autophagic balance that is characterized by AV accumulation containing incom‐
pletely degraded materials and increased levels of p62 (Alegre-Abarrategui et al., 2009).
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Accordingly, siRNA-mediated knockdown of LRRK2 expression results in increased auto‐
phagic activity and prevented cell death caused by inhibition of autophagy in starvation
conditions. Thus, the precise role of autophagy in LRRK2-related parkinsonism is anybody’s
guess at this moment, begging again caution in the proposed use of autophagy inducers as a
therapeutic recourse.
In a related development, we recently found that disease-associated LRRK2 G2019S mutant
can trigger marked mitochondrial abnormalities when overexpressed in Drosophila, a pheno‐
type that can be rescued by parkin co-expression (Ng et al., 2012). Given the role of parkin in
promoting mitophagy, it is tempting to speculate that the LRRK2 mutant may retard the
clearance of damaged mitochondria via mitophagy in the absence of parkin overexpression.
Indeed, the mitochondrial phenotype LRRK2 G2019S mutant induces in the flight muscle is
reminiscent of that brought about by the loss of parkin function. Alternatively, this could also
be a result of LRRK2-induced impairment in autophagy in general. Importantly, we further
found that pharmacological or genetic activation of AMPK can effectively compensate for
parkin deficiency to bring about a significant suppression of dopaminergic and mitochondrial
dysfunction in mutant LRRK2 flies (Ng et al., 2012). Our results suggest a neuroprotective role
for AMPK that might be related to mitophagy/autophagy modulation. AMPK is an evolutio‐
narily conserved cellular energy sensor that is activated by ATP depletion or glucose starvation
(Hardie, 2011). When activated, AMPK switches the cell from an anabolic to a catabolic mode
and in so doing, helps to regulate diverse cellular processes that impact on cellular energy
demands. Interestingly, like parkin, AMPK can also regulate mitophagy and also autophagy
through its ability to phosphorylate the autophagy initiator ATG1 (Egan et al., 2011; Kim et
al., 2011). Lending relevance to our findings, a recent report demonstrated that AMPK is
activated in mice treated with MPTP and that inhibition of AMPK function by compound C
enhances MPP(+)-induced cell death (Choi et al., 2010). More recently, a PD cohort-based study
revealed that Metformin-inclusive sulfonylurea therapy reduces the risk for the disease
occurring with Type 2 diabetes in a Taiwanese population (Wahlqvist et al., 2012). Metformin
is a direct activator of AMPK. Together, these findings suggest that AMPK activation may
protect against the development of PD, presumably via its ability to maintain energy balance
via the modulation of autophagy as well as a range of other cellular processes. Given that
caveats associated with direct autophagy induction, and that excessive autophagy can result
in energy crisis especially in the aged brain, perhaps AMPK activation, through its ability to
maintain both protein and energy homeostasis, would represent a better approach than direct
autophagy induction as a therapeutic strategy for PD.
7. Conclusion
In essence, the case for autophagy dysfunction as a contributor to the pathogenesis of PD is
rather compelling. As evident from the above discussion, virtually all the major PD-associated
gene products have some direct or indirect relationship with the autophagy-lysosome axis.
What is less clear is whether autophagy induction is neuroprotective or is a key driver of
neurodegeneration. One can envisage that the activation of autophagy may be beneficial in
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the short term (particularly when the induction is transient and timely), but deleterious when
it is becomes chronic or excessive. Finding the tipping autophagy threshold point between
neuroprotection and neurodegeneration would therefore be an important endeavour, the
clarification of which has important implications for the future development of autophagy-
related therapeutics for the PD patient.
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